DEVELOPMENT AND VALIDATION OF THE METHOD FOR DETERMINATION OF RAMIPRIL AND HYDROCHLOROTHIAZIDE FOR THE STUDY OF DISSOLUTION PROFILES

Authors

  • K. V. Typlynska I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, JSC “FARMAK”
  • L. S. Logoyda I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY

DOI:

https://doi.org/10.11603/mcch.2410-681X.2024.i1.14606

Keywords:

ramipril, hydrochlorothiazide, tablets, liquid chromatography, dissolution profiles

Abstract

Introduction. When developing generic drugs, it is important to compare their dissolution profiles with the dissolution profiles of the original drug. Therefore, it is important to develop fast and sensitive methods for studying dissolution profiles.

The aim of the study – to develop and validate an analytical procedure for the simultaneous determination of ramipril and hydrochlorothiazide by liquid chromatography, which can be used to study the dissolution profiles of combined drugs.

Research Methods. The research used standard samples of ramipril and hydrochlorothiazide (USP RS), class A reagents, tablets of Ramipril with Hydrochlorothiazide 2.5 mg/12.5 mg and 10 mg/25 mg. The samples were analyzed on a liquid chromatograph with an Agilent 1260 diode array detector. An Inertsil ODS-3 column (4.6 × 150 × 3 μm) was used; mobile phase A – 0.2 g/l sodium hexanesulfonate solution (pH 2.7); mobile phase B: acetonitrile; mobile phase speed 1.5 ml/min; detection wavelength - 210 nm; column temperature – 45 °C, gradient elution mode.

Results and Discussion. A technique for the simultaneous determination of ramipril and hydrochlorothiazide by liquid chromatography in 4 dissolution media (0.1 M hydrochloric acid solution and buffer solutions of pH 1.2, pH 4.5, and pH 6.8) was developed. The developed method has sufficient linearity, accuracy and precision and is robust to minor changes in chromatography conditions. The sensitivity of the method is 0.2 μg/ml for ramipril and 0.4 μg/ml for hydrochlorothiazide. The studied range allows using the method for dosages from 2.5 to 10 mg of ramipril and from 12.5 to 25 mg of hydrochlorothiazide.

Conclusions. The developed technique can be used for simultaneous determination of ramipril and hydrochlorothiazide to study dissolution profiles of the combined dosage form.

References

Global report on hypertension: the race against a silent killer. World Health Organization 2023 Access mode: https://www.who.int/publications/i/item /9789240081062 (accessed on 25 March 2024).

Guideline for the pharmacological treatment of hypertension in adults: summary. World Health Orga­nization 2022 Access mode: https://iris.who.int/bitstream/handle/10665/356108/9789240050969-eng.pdf?se­quence=1 (accessed on 25 March 2024).

Biopharmaceutics classification system-based biowaivers (M9). ICH harmonised guideline Access mode: https://database.ich.org/sites/default/files/M9_Guideline_Step4_2019_1116.pdf (accessed on 25 March 2024).

Bhushan, B., Gupta, S., Khajuria, V., Kumar, D., La M., Kumar, D., Bhat, S., & Sharma, A. (2014). Com­parative Efficacy and Safety of Triple Therapy (Ramipril, Telmisartan, Hydrochlorothiazide) Vs Dual Anti Hyper­tensive Therapy (Ramipril or Telmisartan, Hydro­chloro­thiazide) in Stage 2 Hypertensive Patients. Journal of Clinical and Diagnostic Research, 8(8), 25-28.

Heidbreder, D., Froer, K.L., Bauer, B., Cairns V. & Breitstadt, A. (1991). Efficacy and Safety of Ramipril in Combination with Hydrochlorothiazide Results of a Long-Term Study. Journal of Cardiovascular Pharmacology, 18(2), 169-173.

Pharmacopeia, U. S., & Pharmacopeia, U. S. (2023 Issue 3) National Formulary, The United States Pharmacopeial Convention. Inc., Rockville, MD. Access mode: https://online.uspnf.com/uspnf/section/mono­graphs-usp (accessed on 25 March 2024).

Alahmad, S., Elfatatry, H.M., Mabrouk, M.M., Hammad, S.F., & Mansour, F.R. (2017). Development and Validation of Novel RP-HPLC Method for Simulta­neous Determination of Ramipril, Hydrochlorothiazide and Bisoprolol in Ternary Combinations. Der Pharma Chemica, 9(20), 70-75.

Nagavi, J.B. & Anantharaju, P.G. (2014) Analytical RP-HPLC method development and validation for the simultaneous estimation of ramipril and hydrochlorothiazide in tablet dosage form. American Journal of PharmTech Research, 4(4), 349-365.

Raut, P.V., Padwal, S.L., Bachute, M.T. & Polshettiwar, S.A. (2021) Development and validation of RP-HPLC chromatographic dissolution method for the simultaneous estimation of ramipril and hydrochlorothiazide from solid dosage formulation. Journal of Pharmaceutical Research International, 33(42B), 203-217.

Zaid, A. N., Ghanem, M., Maqboul, L., Zaid, H. & Mahasne A. (2016) Biowaiver eligibility of a lower strength Ramipril/Hydrochlorothiazide immediate release tablets using a new validated HPLC analytical method. Drug Research, 66(10), 539-546.

State Register of Medicinal Products of Ukraine http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument&atscode=C09BA0 (accessed on 25 March 2024).

Typlynska, K., Kondratova, Y., & Logoyda, L. (2023). Development of Methods of Quality Control of the Tablets “Ramipril”. Scientia Pharmaceutica,91(2), 21.

Published

2024-04-29

How to Cite

Typlynska, K. V., & Logoyda, L. S. (2024). DEVELOPMENT AND VALIDATION OF THE METHOD FOR DETERMINATION OF RAMIPRIL AND HYDROCHLOROTHIAZIDE FOR THE STUDY OF DISSOLUTION PROFILES. Medical and Clinical Chemistry, (1), 124–133. https://doi.org/10.11603/mcch.2410-681X.2024.i1.14606

Issue

Section

ORIGINAL INVESTIGATIONS